Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $22.79, for a total value of $91,160.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Thomas Gad also recently made the following trade(s):
- On Monday, June 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $20.03, for a total value of $80,120.00.
- On Tuesday, May 28th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $20.21, for a total value of $121,260.00.
- On Monday, May 13th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $20.61, for a total value of $123,660.00.
- On Thursday, April 11th, Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $25.89, for a total value of $6,472,500.00.
Shares of YMAB stock traded up $0.15 on Wednesday, hitting $22.71. 1,297 shares of the stock were exchanged, compared to its average volume of 89,548. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.30 and a current ratio of 13.30. The company has a market capitalization of $738.58 million and a price-to-earnings ratio of -14.97. Y-mAbs Therapeutics, Inc has a one year low of $15.17 and a one year high of $31.00.
Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.11). Equities analysts predict that Y-mAbs Therapeutics, Inc will post -1.95 EPS for the current year.
A number of research analysts have issued reports on YMAB shares. Zacks Investment Research downgraded Y-mAbs Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 9th. HC Wainwright started coverage on Y-mAbs Therapeutics in a research note on Monday, April 1st. They issued a “buy” rating and a $36.00 price objective for the company. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $30.80.
Several hedge funds have recently bought and sold shares of the company. Northern Trust Corp grew its stake in shares of Y-mAbs Therapeutics by 8.2% during the 1st quarter. Northern Trust Corp now owns 81,492 shares of the company’s stock worth $2,136,000 after acquiring an additional 6,163 shares during the period. BlackRock Inc. grew its stake in shares of Y-mAbs Therapeutics by 8.0% during the 1st quarter. BlackRock Inc. now owns 369,159 shares of the company’s stock worth $9,676,000 after acquiring an additional 27,328 shares during the period. New York State Common Retirement Fund bought a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth $63,000. TD Asset Management Inc. grew its stake in shares of Y-mAbs Therapeutics by 24.1% during the 1st quarter. TD Asset Management Inc. now owns 22,829 shares of the company’s stock worth $598,000 after acquiring an additional 4,432 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth $38,000. Institutional investors own 24.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2019/06/12/y-mabs-therapeutics-inc-nasdaqymab-insider-thomas-gad-sells-4000-shares.html.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.